Patient no. | Sex | Age (y) | Histology | Primary lesion (cm) | Staging | T/Nr | T/Nm |
---|---|---|---|---|---|---|---|
1 | F | 52 | Adenocarcinoma | 2.0 | T1 N3 | 2.54 | 5.56 |
2 | M | 51 | Squamous cell carcinoma | 4.2 | T2 N3 | 2.24 | 6.62 |
3 | M | 57 | Squamous cell carcinoma | 3.0 | T2 N0 | 4.1 | 9.86 |
4 | M | 75 | Adenosquamous carcinoma | 4.8 | T4 N0 | 3.91 | 7.34 |
5 | F | 55 | Adenocarcinoma | 3.6 | T2 N3 M1 | 3.29 | 5.46 |
6 | M | 59 | Adenocarcinoma | 4.2 | T3 N3 | 2.82 | 6.35 |
7 | M | 76 | Undifferentiated lung cancer | 11.0 | T4 N3 | 5.58 | 10.56 |
8 | M | 72 | Adenocarcinoma | 3.8 | T2 N1 | 2.30 | 5.32 |
9 | F | 65 | Adenocarcinoma | 5.2 | T4 N3 M1 | 3.78 | 8.23 |
10 | F | 61 | Squamous cell carcinoma | 3.2 | T2 N0 M1 | 4.06 | 7.16 |
11 | M | 42 | Squamous cell carcinoma | 6.2 | T4 N3 M1 | 4.61 | 5.35 |
12 | M | 70 | Squamous cell carcinoma | 7.8 | T4 N3 | 3.36 | 10.23 |
13 | F | 60 | Squamous cell carcinoma | 5.3 | T2 N3 | 2.98 | 9.18 |
14 | M | 71 | Squamous cell carcinoma | 3.5 | T2 N2 | 3.63 | 6.45 |
15 | M | 75 | Adenocarcinoma | 4.8 | T4 N3 M1 | 2.57 | 4.12 |
16 | M | 70 | Squamous cell carcinoma | 8.5 | T4 N3 | 3.59 | 5.36 |
17 | F | 63 | Adenocarcinoma | 3.5 | T2 | 3.87 | 4.96 |
18 | M | 64 | Adenocarcinoma | 4.5 | T2 N3 M1 | 2.68 | 5.09 |
19 | M | 64 | Small-cell lung carcinoma | 6.5 | T3 N2 | 3.42 | 4.49 |
20 | F | 64 | Adenocarcinoma | 3.8 | T2 N3 M1 | 2.62 | 5.54 |
21 | M | 60 | Adenocarcinoma | 7.1 | T3 N2 | 2.68 | 5.31 |
22 | M | 71 | Adenocarcinoma | 4.5 | T2 N3 M1 | 4.13 | 6.23 |
23 | F | 44 | Small-cell lung carcinoma | 5.0 | T3 N3 M1 | 3.32 | 5.16 |
24 | M | 70 | Squamous cell carcinoma | 8.5 | T4 N3 | 3.36 | 7.16 |
25 | M | 73 | Adenocarcinoma | 5.1 | T2 N0 | 2.89 | 4.86 |
26 | M | 54 | Squamous cell carcinoma | 7.5 | T4 N3 M1 | 3.46 | 8.19 |
27 | M | 76 | Adenocarcinoma | 3.2 | T4 N0 | 3.78 | 4.61 |
28 | M | 51 | Small-cell lung carcinoma | 7.1 | T4 N3 M1 | 3.63 | 5.34 |
29 | M | 75 | Small-cell lung carcinoma | 2.8, 5.6 | T4 N0 M1 | 3.98 | 4.55 |
30 | F | 56 | Small-cell lung carcinoma | 2.0, 5.0 | T2 N0 M1 | 3.68 | 3.99 |
31 | F | 39 | Small-cell lung carcinoma | 3.2 | T4 N0 | 4.09 | 5.32 |
32 | F | 51 | Fibroma | 1.2 | — | 1.29 | 1.42 |
33 | F | 66 | Tuberculosis | 3.3 | — | 1.13 | 2.10 |
34 | F | 70 | Granuloma | 2.3 | — | 1.56 | 3.92 |
35 | F | 62 | Hamartoma | 1.6 | — | 1.49 | 2.13 |
36 | M | 62 | Tuberculosis | 1.2 | — | 1.36 | 3.88 |
37 | M | 83 | Pneumonia | 2.5 | — | 1.78 | 1.89 |
38 | M | 75 | Interstitial pneumonitis | 1.0 | — | 1.39 | 1.78 |
39 | M | 46 | Clear cell tumor | 2.5 | — | 1.24 | 4.12 |
40 | M | 75 | Tuberculosis | 4.0 | — | 1.35 | 3.89 |
41 | M | 30 | Tuberculosis | 1.5 | — | 4.69 | 6.93 |
42 | M | 71 | Granuloma | 2.5 | — | 1.59 | 1.89 |
43 | M | 68 | Tuberculosis | 2.6 | — | 3.68 | 4.96 |
44 | M | 50 | Tuberculosis | 3.0 | — | 3.89 | 5.69 |
TNM staging was determined by histopathology or other imaging modalities. Tumor-to-normal tissue uptake ratios of 18F-FDG DHC are expressed as T/Nm. Tumor-to-normal tissue uptake ratios of 99mTc-octreotide imaging are expressed as T/Nr.